This webinar was the first in a three-part educational series for emerging cell and gene therapy companies.
On June 25, the CEO Council for Growth, in partnership with IntegriChain, hosted a webinar on Launch Readiness for Cell & Gene Therapies in the Government & Commercial Channels. Presented by Jeffrey Baab, IntegriChain Executive Director, Advisory Services, the virtual event featured product launch preparedness advice for cell and gene therapy pricing and contracting professionals.
Headquartered in Philadelphia, IntegriChain is a CEO Council member that provides patient and payer data analytics and advisory services to manufacturers across the globe.
The hour-long webinar was the first in a complimentary three-part educational series that focuses on topics relevant to emerging cell and gene therapy companies. A recording of the June 25 event is available here (Password: IntegriChain#20200625) for those unable to attend live.
During the launch readiness event, Baab provided an overview of commercial and government markets and covered topics that included factors influencing market access, cell and gene therapy market access models, and unique challenges of the industry.
With emerging cell and gene therapies, Baab told attendees, every product launch will require a unique approach. “A lot of the market structures we have in place today simply weren’t built to support cell and gene therapies,” said Baab.
Baab also cautioned that product launches will likely require a lengthier planning process for both commercial and government channels. He advised attendees to plan for both strategic and operational challenges when looking to finance cell and gene therapies.
Additionally, since cell and gene therapy is an emerging market, the commercial and regulatory landscape is changing fast. “Keep in touch with what is happening and changing from the regulatory and commercial perspective,” said Baab.
In closing, Baab commented on the evolving nature of the cell and gene therapies market. New products are regularly being launched, regulations are constantly changing, and cell and gene therapy distributors must be prepared to identify and adapt to new challenges as they arise.
To watch a recording of the webinar on Launch Readiness for Cell & Gene Therapies in the Government & Commercial Channels, click here.
Upcoming events in the Educational Series for Emerging Cell & Gene Therapy Companies brought to you by the CEO Council for Growth in Partnership with IntegriChain:
Contracting Implications for Cell & Gene Therapies
This webinar examines the unique pricing and contracting strategies that can impact government program access of cell and gene therapies. The webinar will be held at 1 p.m. EST on Thursday, July 16, 2020.
Gross-to-Net Launch Readiness for Cell & Gene Therapies
This webinar focuses on mission-critical gross-to-net systems and forecasting activities for cell and gene therapy companies planning for commercial launch. The webinar will be held at 1 p.m. EST on August 20, 2020.
For information on registration, visit integrichain.com/webinar-series-for-emerging-cell-gene-therapies-companies/.